What You Need to Know About the J&J Vaccine Blood Clot Risk

Publikováno: 13.4.2021

#vaccine #janet woodcock #adenoviridae #health medical pharma #johnson johnson covid 19 vaccine #johnson #megan ranney #johnson johnson #covid 19 #health sciences #pfizer #vaccination #moderna #astrazeneca #covid 19 vaccines #oxfordastrazeneca covid 19 vaccine #medicine #c

Celý článek

Six people, out of over 6 million who have received the Johnson & Johnson/Janssen COVID vaccine, have developed a rare type of blood clot. As a result, the FDA and CDC have announced a pause in the use of this vaccine. The pause is likely to last just a few days.